Compare · CCEL vs MRAI
CCEL vs MRAI
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Marpai Inc. (MRAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and MRAI operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- CCEL is the larger of the two at $83.3M, about 1.9x MRAI ($43.5M).
- MRAI has been more active in the news (9 items in the past 4 weeks vs 1 for CCEL).
- Company
- Cryo-Cell International Inc.
- Marpai Inc.
- Price
- $3.41-1.16%
- $0.92-55.67%
- Market cap
- $83.3M
- $43.5M
- 1M return
- -3.67%
- -
- 1Y return
- -36.14%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 1
- 9
- Recent ratings
- 0
- 0
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Latest CCEL
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Latest MRAI
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)
- Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)
- Director Pons Robert M returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 9% to 484,200 units (SEC Form 4)
- Director Calabrese Jennifer Rosario returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 18% to 225,000 units (SEC Form 4)
- Chief Executive Officer Lamendola Damien was granted 300,000 shares, increasing direct ownership by 22% to 1,650,000 units (SEC Form 4)
- Director Diclaudio Colleen was granted 125,000 shares, increasing direct ownership by 88% to 267,500 units (SEC Form 4)
- Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026
- Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)
- SEC Form 10-Q filed by Marpai Inc.